Carbamazepine in mixed frontal lobe and psychiatric disorders

Abstract

Carbamazepine was given to five patients with mixed frontal lobe disease and a variety of primary psychiatric disorders. All five patients benefited significantly. A decrease in affective lability was the most consistent result. Carbamazepine may be an alternative to chronic high-dose neuroleptic therapy in these patients.